

PERSONAL INFORMATION

Osamah Hamouda



Sex Male | Nationality German / Egyptian

WORK EXPERIENCE

- November 2013 - present **Head of Department for Infectious Disease Epidemiology**
 Robert Koch Institute, Berlin (Germany)
 National Infectious disease research and surveillance
- January 2003 –October 2013 **Deputy Head, Department of Infectious Disease Epidemiology, Head of HIV/AIDS, STI and Bloodborne Infections Unit**
 Robert Koch Institute, Berlin (Germany)
- July 2001 – December 2002 **Deputy Head “Centre for Infectious Disease Epidemiology”**
 Robert Koch Institute, Berlin (Germany)
 HIV/AIDS, STI, Hepatitis B and –C, CJK/ vCJK, TB and nosocomial Infections; surveillance , outbreak investigation, training supervisor
- July 1998 - June 2001 **Senior Epidemiologist, HIV/AIDS, STI and TB; Head of AIDS working group**
 Robert Koch Institute, Berlin (Germany)
 HIV/AIDS, STI, Hepatitis B and –C, Blood donor surveillance; Infectious disease research and surveillance, lead investigator German HIV1 Seroconverter Study (monitoring of transmitted drug resistance) and Clinical Surveillance of HIV (ClinSurv) national observational cohort
- May 1995 – June 1998 **Senior Epidemiologist, Head of HIV/AIDS and STD Surveillance Unit**
 Robert Koch Institute, Berlin (Germany)
 HIV/AIDS and STI surveillance
- August 1990 – April 1995 **Medical Epidemiologist, Epidemiology Unit, National AIDS-Centre**
 Federal Health Office (Bundesgesundheitsamt), Berlin
 HIV/AIDS surveillance
- June 1987 - July 1990 **Physician, AIDS prevention programme**
 Senator für Gesundheit und Soziales, Berlin (Health Administration, City of Berlin)
 Health education, counselling, HIV/AIDS prevention

EDUCATION AND TRAINING

- 1992-1994 **Master in Public Health (MPH)**
 Technische Universität, Berlin (Germany)
- May 1987 **Dissertation (Dr. med.)**
 Institute for Perinatal Medicine, University Clinic Neukölln, Berlin, Germany

- August 1985 **Medical Doctor (Approbation, licence to practice medicine)**
Free University, Berlin (Germany)
- 1978-1985 **Preclinical and clinical medical training**
Free University Berlin, Germany

PERSONAL SKILLS

Mother tongue(s) **German**

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C2	C2	C2	C2	C2
French	A2	B1	A1	A1	A1

Replace with name of language certificate. Enter level if known.

Levels: A1/2: Basic user - B1/2: Independent user - C1/2 Proficient user
Common European Framework of Reference for Languages

Communication skills ▪ Good ability to adapt to multicultural environments, gained through my work in European and international networks

Organisational / managerial skills ▪ Leadership and management (currently directly responsible for a department of 170 people)

ADDITIONAL INFORMATION

Publications ▪ Recent peer reviewed publications (selection)

1. Machnowska P, Meixenberger K, Schmidt D, Jessen H, Hillenbrand H, Gunsenheimer-Bartmeyer B, Hamouda O, Kucherer C, Bannert N (2019): revalence and persistence of transmitted drug resistance mutations in the German HIV-1 Seroconverter Study Cohort. *PLoS One*, 14 (1): e0209605.
2. Willemse S, Smit C, Sogni P, Sarcletti M, Uberti-Foppa C, Wittkop L, Raben D, D'Arminio Monforte A, Dabis F, van der Valk M, Judd A, Zangerle R, Touloumi G, Warszawski J, Meyer L, Dabis F, Murielle M, Ghosn J, Lepout C, Wittkop L, Reiss P, Wit F, Prins M, Bucher H, Gibb D, Fätkenheuer G, Obel N, Thorne C, Mocroft A, Kirk O, Stephan C, Pérez-Hoyos S, Hamouda O et al: (2019): Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis. *Journal of Viral Hepatitis*. (in Press)-
3. Migrant Health Working Group for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord (for RKI: Bartmeyer B, **Hamouda O**) (2018): Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all? *HIV Med.*: 19 (1): 42-48.
4. Pineda-Pena AC, Theys K, Stylianou DC, Demetriades I; SPREAD/ESAR Program (for RKI: **Hamouda O**), Abecasis AB, Kostrikis LG (2018): HIV-1 infection in Cyprus, the Eastern Mediterranean European frontier: a densely sampled transmission dynamics analysis from 1986 to 2012. *Sci. Rep.* 8 (1): 1702.
5. *Stirrup OT, Copas AJ, Phillips AN et al.; CASCADE Collaboration in EuroCoord (for RKI **Hamouda O**, Meixenberger K, Bannert N, Bartmeyer B) (2018): Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion. *HIV Med.* 19 (3): 184-194.*
6. Chereau F, Madec Y, Sabin C, Obel N, Ruiz-Mateos E, Chrysos G, Fidler S, Lehmann C, Zangerle R, Wittkop L, Reiss P, **Hamouda O** et al.; HIV Controllers Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCOORD (2017): Impact of CD4 and CD8 dynamics HIV controllers. *PLoS One* 12 (4): e0173893.

7. Dudareva-Vizule S, Haar K, Sailer A, Jansen K, **Hamouda O**, Wisplinghoff H, Tiemann C, Pape E, Bremer V (2017): Chlamydia trachomatis laboratory sentinel team. Establishment of a voluntary electronic Chlamydia trachomatis laboratory surveillance system in Germany, 2008 to 2014. *Euro Surveill.*; 22 (6): pii=30459.
8. Ghosn J, Bayan T, Meixenberger K (for RKI: **Hamouda O**, Meixenberger K, Bannert N, Bartmeyer B) (2017): CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. *Journal of Antimicrobial Chemotherapy*; 72 (10): 2862-2868.
9. Hofmann A, Hauser A, Zimmermann R, Santos-Hövenner C, Bätzing-Feigenbaum J, Wildner S, Kücherer C, Bannert N, **Hamouda O**, Bremer V, Bartmeyer B (2017): Surveillance of recent HIV infections among newly diagnosed HIV cases in Germany between 2008 and 2014. *BMC Infectious Diseases*; 17 (1): 484.
10. Karo B, Krause G, Castell S, Kollan C, **Hamouda O**, Haas W; ClinSurv HIV Study Group (2017): Immunological recovery in tuberculosis/HIV co-infected patients on antiretroviral therapy: implication for tuberculosis preventive therapy. *BMC Infect. Dis.* 17: 517.
11. Meixenberger K, Yousef KP, Smith MR, Somogyi S, Fiedler S, Bartmeyer B, **Hamouda O**, Bannert N, von Kleist M, Kücherer C (2017): Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors. *Virology*. 14 (1): 223.
12. Ziese T, **Hamouda O** (2017): Surveillance und Monitoring: *Gesundheitswesen*; 79 (11): 932-935.
13. Höller C, Jacobshagen A, **Hamouda O**, Abu Sin M, Monnet DL, Plachouras D, Eckmanns T (2016): Contamination during production of heater-cooler units by Mycobacterium chimaera potential cause for invasive cardiovascular infections: results of an outbreak investigation in Germany, April 2015 to February 2016. *Euro Surveill.* ; 21(17): pii=30215.
14. Hofstra LM, Sauvageot N, Albert J, Alexie I, Garcia F, Struck D, Van De Vijver DAMC, Åsjö B, Beshkov D, Coughlan S, Descamps D, Griskevicius A, **Hamouda O** et al for the SPREAD Team (for RKI: Kücherer C, Poggensee G, Günsenheimer-Bartmeyer B) (2016): Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe. *Clinical Infectious Diseases*; 62 (5): 655-663.
15. Karo B, Krause G, Hollo V, van der Werf MJ, Castell S, **Hamouda O**, Haas W (2016): The impact of HIV infection on treatment outcome of tuberculosis: analysis of surveillance data from nine European countries, 2010–2012. *AIDS*; 30 (4): 1089-1098.
16. Magiorkinis G, Angelis K, Mamais I, Katzourakis A, Hatzakis A, Albert J, Lawyer G, **Hamouda O** et al. (2016): The global spread of HIV-1 subtype B epidemic. *Infect. Genet. Evol.*: Epub Jun 2.
17. Yousef KP, Meixenberger K, Smith MR, Somogyi S, Gromöller S, Schmidt D, Günsenheimer-Bartmeyer B, **Hamouda O**, Kücherer C, von Kleist M (2016): Inferring HIV-1 transmission dynamics in Germany from recently transmitted viruses. *Journal of Acquired Immune Deficiency Syndromes*; 73 (3): 356-363.
18. Wenz B, Nielsen S, Gassowski M, Santos-Hövenner C, Cai W, Ross R, Bock C-T, Ratsch B-A, Kücherer C, Bannert N, Bremer V, **Hamouda O**, Marcus U, Zimmermann R, the DRUCK Study group. (2016): High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities. *BMC Public Health*; 16 (1): 1-14.
19. An der Heiden M, Ritter S, **Hamouda O**, Offergeld R (2015): Estimating the residual risk for HIV, HCV and HBV in different types of platelet concentrates in Germany. *Vox Sanguinis*; 108 (2):123-130.
20. Angelis K, Albert J, Mamais I, Magiorkinis G, Hatzakis A, **Hamouda O** et al. (2015): Global dispersal pattern of HIV-1 CRF01_AE: A genetic trace of human mobility related to heterosexual activities centralized in South-East Asia. *J. Infect. Dis.*: 211 (11): 1735-44.
21. Beermann S, Allerberger F, Wirtz A, Burger R, **Hamouda O** (2015): Public health microbiology in Germany: 20 years of national reference centers and consiliary laboratories. *International Journal of Medical Microbiology*. 305 (7): 595-600.
22. **Hamouda O** (2015): Erarbeitung eines Nationalen Aktionsplans 2015-2020 zur Elimination der Masern und Röteln in Deutschland. *Pädiatrische Praxis*. 85 (1): 15-20.
23. **Hamouda O** (2015): So breitet sich HIV in Deutschland aus. *MMW Fortschr. Med.* 157 (Suppl. 2): 10-13.
24. Jansen K, Thamm M, Bock C-T, Scheufele R, Kücherer C, Muenstermann D, Hagedorn H-J, Jessen H, Dupke S, **Hamouda O**, Günsenheimer-Bartmeyer B, et al. (2015) High Prevalence and High Incidence of Coinfection with Hepatitis B, Hepatitis C, and Syphilis and Low Rate of Effective Vaccination against Hepatitis B in HIV-Positive Men Who Have Sex with Men with Known Date of HIV Seroconversion in Germany. *PLoS ONE* 10 (11): e0142515.

25. Monge S, Jarrin I, Mocroft A, Sabin CA, Touloumi G, van Sighem A, Abgrall S, Dray-Spira R, Spire B, Castagna A, Mussini C, Zangerle R, Hesse M, Anderson J, **Hamouda O** (2015): Mortality in migrants living with HIV in western Europe (1997-2013): A collaborative cohort study. *The Lancet HIV*; 2 (12): e540-e549.
26. Santos-Hövenner C, Marcus U, Koschollek C, Oudini H, Wiebe M, Idrissa Ouedraogo O, Thorle A, Bremer V, **Hamouda O**, Dierk M-L, an der Heiden M, Krause G (2015): Determinants of HIV, viral hepatitis and STI prevention needs among African migrants in Germany; a cross-sectional survey on knowledge, attitudes, behaviors and practices. *BMC Public Health*; 15: 753.
27. Santos-Hövenner C, Marcus U, Koschollek C, Oudini H, Wiebe M, Ouedraogo OI, Mayamba P, M'bayo R, Sanogo A, Bakambamba A, Gangarova T, **Hamouda O**, Dierks M-L, Krause G (2015): Konzeption einer Studie zu sexueller Gesundheit bei in Deutschland lebenden Afrikanern. *Prävention und Gesundheitsförderung*, 10 (1): 68-75.
28. Schmidt D, Kollan C, Stoll M, Stellbrink HJ, Plettenberg A, Fätkenheuer G, Bergmann F, Bogner JR, van Lunzen J, Rockstroh J, Esser S, Jensen BE, Horst HA, Fritzsche C, Kühne A, An der Heiden M, **Hamouda O**, Bartmeyer B; ClinSurv Study Group (2015): From pills to patients: an evaluation of data sources to determine the number of people living with HIV who are receiving antiretroviral therapy in Germany. *BMC Public Health* 15: 252.
29. Schöfer H, Weberschock T, Bräuninger W, Bremer V, Dreher A, Enders M, Esser S, **Hamouda O** et al. (2015): S2k-Leitlinie* „Diagnostik und Therapie der Syphilis“ – Kurzfassung. *J. Dtsch. Dermatol. Ges.* 13 (5): 472–481.
30. Vogel U, Beermann S, Gerlich W, **Hamouda O**, Kempf V A J, Slack M (2015): Twenty years of National Reference and Consultant laboratories for Infectious Diseases in Germany, *International Journal of Medical Microbiology* 305 (7): 591-594.